Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 3016 (116th)

Liver Illness Visibility, Education, and Research Act of 2019

referredUnited States· United States Congress· EN

Introduced

23 May 2019

Last action

24 May 2019 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Velázquez, Nydia M. [D-NY-7], Rep. Espaillat, Adriano [D-NY-13], Rep. Lee, Barbara [D-CA-12], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Gabbard, Tulsi [D-HI-2], Rep. Vela, Filemon [D-TX-34], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Meeks, Gregory W. [D-NY-5], Rep. Thompson, Bennie G. [D-MS-2], Rep. Jackson Lee, Sheila [D-TX-18], Rep. Mucarsel-Powell, Debbie [D-FL-26], Rep. Cohen, Steve [D-TN-9], Rep. Harder, Josh [D-CA-9], Rep. Lieu, Ted [D-CA-36], Rep. Ruppersberger, C. A. Dutch [D-MD-2], Rep. Delgado, Antonio [D-NY-19], Rep. Lamb, Conor [D-PA-17]

Subjects

Healthcare, Education

Source updated

5 December 2025

Healthcare · Education

Official sourceDownload fileView documentsShare

Summary

Liver Illness Visibility, Education, and Research Act of 2019 This bill expands and coordinates activities related to the research of liver cancer and liver disease, including causes, prevention, detection, and treatment. Specifically, the National Cancer Institute must establish an inter-institute working group to coordinate efforts to cure liver cancer and liver disease, including research into such cases resulting from hepatitis B, and may award grants to develop preventative and diagnostic measures as well as support for experimental treatment options. The bill further establishes grant programs, administered by the Centers for Disease Control and Prevention, to support liver disease prevention services, diagnostics, and hepatitis tracking programs and to raise awareness about liver disease within high-risk communities. The renamed National Institute of Diabetes and Digestive, Kidney, and Liver Diseases also must prioritize programs addressing liver disease, including (1) establishing a national clearinghouse for patient data and (2) developing or expanding the centers for research of liver disease.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 23 May 2019

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 23 May 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 23 May 2019

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 24 May 2019

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 23 May 2019

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 23 May 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 23 May 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.